Fractionated Stereotactic Radiotherapy in Patients With Acromegaly. Single Centre Experience
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Tumour control by pituitary MRI
研究概览
简要总结
Hypothesis: Fractionated stereotactic radiotherapy is a safe therapy for treatment of patients with acromegaly in terms of both tumour control and biochemical remission
详细描述
An audit was done on 34 patients with acromegaly (consecutive cohorte) treated with fractionated stereotactic radiotherapy in Rigshospitalet/National University Hospital, Copenhagen, Denmark. All patients had MR control regularly to monitor tunour control, and biochemical control assessed by growth hormone measurements during an oral glucose tolerance test. Furthermore all other pituitary axes were tested for sufficiency and concomitant medication likewise registered. The 7 year interim analysis demonstrated an acceptable tumour control and biochemical remission profile, and most patient had subsequent withdrawal of somatostatin analogue- and growth hormone receptor antagonis therapy. The observational study will continue with a new update in approx 2 years
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adults active acromegaly pituitary tumour on MRI biochemical activity -
排除标准
- •pregnancy no visible tumour on MRI
结局指标
主要结局
Tumour control by pituitary MRI
时间窗: 7 years
次要结局
- biochemical remission(10 years)
- withdrawal of somatostatin analogue and growth hormone receptor antagomist(10 years)
- Affection of other pituitary axes(10 years)
研究者
Ulla Feldt-Rasmussen
Professor, chief Physician
Rigshospitalet, Denmark